The 2018 Award Ceremony took place during the XXV EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2018), held on September 2-6, 2018 in Ljubljana, Slovenia.
Nauta Pharmacochemistry Award for Medicinal Chemistry and Chemical Biology
Prof. Christa Müller – University of Bonn, Germany
For her extensive contribution to the field of adenosine and purinergic receptors, from the design of novel ligands to the study of their therapeutic potential, and for her support of the European Medicinal Chemistry community. Dr. Müller is a highly cited scientist who has developed a number of tool compounds now used by many labs around the world. She has set up numerous international collaborations, and is a co-founder of the Pharmacenter in Bonn. Her noted contributions to the Medicinal Chemistry community include continued editorial and advisory duties, educational initiatives, and the organization of international conferences.
After the ceremony on Sunday September 2, Prof. Christa Müller gave a lecture on: Tools and Drugs for Purine Targets - Important Players in Inflammation and Cancer
Prof. Adam Nelson – University of Leeds, United Kingdom
For his ground breaking work to explore novel chemical space, especially natural product-like, diversity-oriented and activity-directed synthesis. Prof. Nelson implemented his vision that chemical synthesis should align with drug discovery needs, and introduced methods that have been taken up by the medicinal chemistry community to profile synthetic targets for lead-likeness and chemical novelty. He plays an important role in the European Lead Factory, chairing its Library Selection Committee, and leads the “Next Generation Chemistry for Medicine” theme at the Rosalind Franklin Institute, in the UK.
On Monday September 3, Prof. Adam Nelson gave a lecture on: How Best to Discover Bioactive Small Molecules?
Prof. Benjamin Cravatt – Scripps Research Institute, USA
For his major contribution to the development of chemical proteomics, and in particular the introduction and refinement of the activity-based protein profiling (ABPP) technology. This novel approach allows the study of enzyme function in complex systems: This, and the efforts of Prof. Cravatt to identify tools for chemical biology, led to the identification of novel therapeutic targets for the treatment of human diseases of the central nervous system.
On Tuesday September 4, Prof. Benjamin Cravatt gave a lecture on: Activity-Based Proteomics - Protein and Ligand Discovery on a Global Scale
Photographer - Fabien Venturi